Introduction

This course introduces the student to the biomedical community as it relates to current strategies undertaken to move research discoveries from the laboratory (bench) into clinical practice (bedside) to diagnose and treat patients. This concept is commonly referred to as Translational Science or Translational Medicine. The tenets of this course will be defined and explained in terms of promoting focused multidisciplinary interactions between science and medicine to enhance disease research and drug development. In addition, the wider inter-relationships with regulatory, ethical and societal sectors will be presented.

Objectives

This course is designed for undergraduates of both scientific and non-scientific majors with an interest in learning about principles and concepts underlying drug discovery and development of medicines. Chapters from the required textbook will be supplemented with a variety of source materials including articles from scientific journals and public websites. Selected cases studies will be critically reviewed and emerging “hot” topics discussed.

Upon successful completion of this course, the student should be able to demonstrate a working knowledge of:

- The importance of a team effort in the drug discovery/drug development process as seen through the eyes of the pharmaceutical industry.
- The many challenges faced by a start-up pharmaceutical company.
- The importance of intellectual property (IP); critical IP issues and timing.
- The preclinical drug development process from therapeutic target to marketable drug.
• The basic terminology used in characterizing a new drug (e.g. potency, EC$_{50}$, IC$_{50}$, MTD, efficacy, selectivity, ADME, etc…).
• The importance of properly designing a scientific experiment (Scientific Method).
• The importance of identifying potential genotoxicity, carcinogenicity and reproductive/developmental toxicology issues during the course of a drug discovery campaign and how to test for them.
• The difference between a small molecule drug and a biopharmaceuticals and understand the advantages and disadvantages of each therapy.
• The importance of good laboratory practices (GLP), good manufacturing practices (GMP) and good clinical practices (GCP).
• The role of clinical trials in drug development.
• Why so many experimental compounds fail to ever reach the market.

Assignments and Grading:

Class participation: 10 pts (5 %)
5 quizzes @ 10 pts each 50 pts (25%)
2 midterm exams @ 40 pts each: 80 pts (40 %)
1 final exam (Essay Assignment): 60 pts (30 %)
Total: 200 pts.

Class Participation and Attendance (10 pts): On a scale of 10, 0-indicating no participation, 10-indicating best participation. You can therefore increase the probability of getting a higher mark by being proactive in terms of asking (relevant) questions in class and/or contributing to discussions.

Attendance at all classes is expected. Participation will include asking and answering questions and being actively involved in the discussion. It is expected that the students read the assigned papers prior to the lecture and be prepared to discuss background, current understanding, treatments, and gaps in knowledge for the topic in each lecture.

There will be 5 quizzes over the course of the semester that will primarily be based on questions pulled from the text book and lectures. The midterms (40 points each) will include multiple choice questions T/F questions fill-in the blank questions, and short answers.

Instead of a final exam, a 5-page double-spaced essay (deliverable) will be due by email to ddavies@usc.edu by 5pm PST on the day of the final (Tuesday, May 7, 2019). The deliverable this year will focus on the discovery, development and use of cancer therapies based on Car-T Therapies.

Within the assignment, you will present the background and history of CAR-T therapies. Briefly, how they work, what are the target cells, etc. I don’t expect you to be a molecular biologist, but as future clinician's this is a therapy that is gaining momentum and it is one that you need to start reading about. Also discuss the advantages (and challenges) for CAR-T therapies. What are the current drug companies that are working on CAR-T therapies? What cancers are they trying to address with these therapies? What is the alternative to these therapies?
How would you address the cost factor of the therapy? Who will pay?

Proper references to the literature (this excludes Wikipedia and the like) are required but do not count against the page limits.

Notes, books, calculators, electronic dictionaries, regular dictionaries, cell phones or any other aids are not allowed during exams.

Students will be asked to complete an anonymous critical evaluation of the course at its completion.

**Course Readings**

**Required Readings**

**Drug Discovery and Development: Technology in Transition, 2nd Edition**
Raymond G. Hill & Humphrey P. Rang; **ISBN-13:** 978-0702042997

Although not mandatory, it is strongly suggested that the students purchase the textbook for this course as it will greatly improve the students grasp on the Drug Discovery/Development process. The students will be able to use identified chapters in the text to support their learning process throughout the semester.

Other course materials including but not limited to the syllabus, supplemental reading assignments and additional handouts will be posted on [http://blackboard.usc.edu/](http://blackboard.usc.edu/). The students will also be encouraged to use the online discussions among students via Blackboard.

**Recommended**


• Dr. Timothy Scott discusses some of the history of the FDA and how it shaped the industry today. https://youtu.be/TXAVCaOSi-s

• Free magazine “Translational Science” https://www.youtube.com/watch?v=9Cw9v-LnrRU&feature=youtu.be

  • Newsletters such as: Drug Discovery Online Newsletter <info@DrugDiscoveryOnline.com>

  • Pharmaceutical Processing: https://www.rdmag.com/topics/pharmaceutical-processing

Course Outline

This course will be in the format of a directed seminar/lecture under the guidance of the instructor for the specific session. During each weekly session the instructor will engage the students with questions and draw comments or interpretations primarily based on the assigned reading. Students are expected to ask questions and participate in an interactive fashion.
<table>
<thead>
<tr>
<th>Week &amp; Date</th>
<th>Topic</th>
<th>Subtopics to be Included</th>
<th>Assigned and Supplemental Reading</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Introduction and Background</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 1</strong> Jan. 14, 16</td>
<td>Introduction: expectations and goals of this class. General overview of drug development process from therapeutic target to marketable drug.</td>
<td>Pharmacological principles and definitions: Efficacy (EC50), potency, MTD, ADME, etc. Market Strategies Case studies illustrating why we have the FDA.</td>
<td>Hill/Rang, Chapter 22. Additional readings to enrich subject matter will be posted on Blackboard.</td>
</tr>
<tr>
<td><strong>Week 2</strong> Jan. 21, 23</td>
<td>Development of Pharmaceutical Industry-</td>
<td>History of drug development (where and how it all got started).</td>
<td></td>
</tr>
<tr>
<td><strong>Week 3</strong> Jan 28, 30</td>
<td>Nature of Disease Quiz 1 Jan 28</td>
<td>Etiology, pathology, research highlights, current drug treatments and future drug development. Therapeutic Interventions; Therapeutic modalities</td>
<td>Hill/Rang, Chapters 2-3</td>
</tr>
<tr>
<td><strong>Drug Discovery</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 4</strong> Feb. 4, 6</td>
<td>Introduction to Drug Discovery</td>
<td>General Principles; Case Histories,</td>
<td>Hill/Rang , Chapter 4</td>
</tr>
<tr>
<td><strong>Week 5</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weeks 5</strong> Feb 11, 13</td>
<td>Defining a Market DD Dr. Robert Pacifici, CHDI</td>
<td>Defining a Market for your Drug Where does it all start? Identifying the Project; Identifying the Target</td>
<td>Hill/Rang , Chapters 5-6</td>
</tr>
<tr>
<td><strong>Week 6</strong> Feb. 18, 20</td>
<td>Project Management of Drug DD Dr. Robert Pacifici, CHDI</td>
<td>Role of CROs in new drug development</td>
<td></td>
</tr>
<tr>
<td><strong>Week 7</strong> Feb. 25, 27</td>
<td>Quiz 2 Feb 25 Dr. Ashutosh Kulkarni, Allergan</td>
<td>Understand the role of drug metabolism and pharmacokinetics (DMPK) and early stage toxicology studies as major hurdles in the drug discovery process; Role of pharmacology (specifically confirmation in vitro assays, target selectivity testing and in vivo pharmacological profiling) in the drug discovery process;</td>
<td>Hill/Rang , Chapters 10-11;13-14</td>
</tr>
<tr>
<td><strong>Week 8</strong> Mar 3, 5</td>
<td>The Components of Drug Discovery Mary Ellen Cosenza</td>
<td>Biopharmaceuticals; Assessing Drug Safety;</td>
<td>Hill/Rang , Chapters 10-11;13-14</td>
</tr>
<tr>
<td><strong>Weeks 9</strong> Mar. 10, Mar 12</td>
<td>Documentation Requirements Quiz 3 will be presentations by students</td>
<td>Why do we care about documentation? cGLP, cGMP GRP – Good Research Practices – adapting good science to the laboratory setting in academia</td>
<td>Hill/Rang , Chapter 12</td>
</tr>
<tr>
<td><strong>Drug Development</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mar. 15-22</strong></td>
<td>No Class</td>
<td>Spring Break</td>
<td></td>
</tr>
<tr>
<td><strong>Week 10</strong> Mar. 24, 26</td>
<td>Pharmaceutical Development Hovik Gukasyan, Allergan</td>
<td>Comprehend different drug delivery systems</td>
<td>Hill/Rang , Chapter 16</td>
</tr>
<tr>
<td>Week 11</td>
<td>Quiz 4 Mar 31</td>
<td>&quot;Clinical development of novel therapeutics&quot;</td>
<td>Hill/Rang, Chapter 17</td>
</tr>
<tr>
<td>---------</td>
<td>---------------</td>
<td>---------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Mar. 31, Apr 2</td>
<td>Anna Papinska, PhD Allergan</td>
<td>&quot;Clinical development of novel therapeutics&quot;</td>
<td>Hill/Rang, Chapter 17</td>
</tr>
<tr>
<td>Week 12</td>
<td>Development products for clinical testing and comparability</td>
<td>Identification of regulatory implications</td>
<td>Hill/Rang, Chapters 19-20</td>
</tr>
<tr>
<td>Apr 7, 9</td>
<td>Future research opportunities</td>
<td>Scale-up/formulation challenges</td>
<td>Hill/Rang, Chapters 19-20</td>
</tr>
<tr>
<td>Week 13</td>
<td>Michael R. Hamrell, PhD</td>
<td>Regulation of Advertising and Promotion for Prescription Drugs</td>
<td>Hill/Rang, Chapter 19</td>
</tr>
<tr>
<td>Apr. 14, 16</td>
<td>Quiz 5 April 21</td>
<td>The use of a drug repurposing strategy to accelerate new opportunities for currently approved drugs in the pharmaceutical industry</td>
<td>Hill/Rang, Chapter 19</td>
</tr>
<tr>
<td>April 21, 23</td>
<td>Drug Repurposing Patents: Importance of IP in Academia</td>
<td>Development Strategies and Considerations for Combination Products.</td>
<td>Hill/Rang, Chapter 19</td>
</tr>
<tr>
<td>Week 15</td>
<td>Michael R. Hamrell, PhD</td>
<td>Development Strategies and Considerations for Combination Products.</td>
<td>Hill/Rang, Chapter 19</td>
</tr>
<tr>
<td>April 28, 30</td>
<td></td>
<td></td>
<td>Hill/Rang, Chapter 19</td>
</tr>
</tbody>
</table>

**Final Exam:** Exam Paper is due by 5:00 pm on May 12th.
Statement on Academic Conduct and Support Systems

Academic Conduct:

Plagiarism – presenting someone else’s ideas as your own, either verbatim or recast in your own words – is a serious academic offense with serious consequences. Please familiarize yourself with the discussion of plagiarism in SCampus in Part B, Section 11, “Behavior Violating University Standards” policy.usc.edu/scampus-part-b. Other forms of academic dishonesty are equally unacceptable. See additional information in SCampus and university policies on scientific misconduct, policy.usc.edu/scientific-misconduct.

Support Systems:

Counseling and Mental Health - (213) 740-9355 – 24/7 on call studenthealth.usc.edu/counseling
Free and confidential mental health treatment for students, including short-term psychotherapy, group counseling, stress fitness workshops, and crisis intervention.

National Suicide Prevention Lifeline - 1 (800) 273-8255 – 24/7 on call suicidepreventionlifeline.org
Free and confidential emotional support to people in suicidal crisis or emotional distress 24 hours a day, 7 days a week.

Relationship and Sexual Violence Prevention and Services (RSVP) - (213) 740-9355(WELL), press “0” after hours – 24/7 on call studenthealth.usc.edu/sexual-assault
Free and confidential therapy services, workshops, and training for situations related to gender-based harm.

Office of Equity and Diversity (OED)- (213) 740-5086 | Title IX – (213) 821-8298 equity.usc.edu, titleix.usc.edu
Information about how to get help or help someone affected by harassment or discrimination, rights of protected classes, reporting options, and additional resources for students, faculty, staff, visitors, and applicants. The university prohibits discrimination or harassment based on the following protected characteristics: race, color, national origin, ancestry, religion, sex, gender, gender identity, gender expression, sexual orientation, age, physical disability, medical condition, mental disability, marital status, pregnancy, veteran status, genetic information, and any other characteristic which may be specified in applicable laws and governmental regulations. The university also prohibits sexual assault, non-consensual sexual contact, sexual misconduct, intimate partner violence, stalking, malicious dissuasion, retaliation, and violation of interim measures.
Reporting Incidents of Bias or Harassment - (213) 740-5086 or (213) 821-8298
usc-advocate.symplicity.com/care_report
Avenue to report incidents of bias, hate crimes, and microaggressions to the Office of Equity and Diversity |Title IX for appropriate investigation, supportive measures, and response.

The Office of Disability Services and Programs - (213) 740-0776
dsp.usc.edu
Support and accommodations for students with disabilities. Services include assistance in providing readers/notetakers/interpreters, special accommodations for test taking needs, assistance with architectural barriers, assistive technology, and support for individual needs.

USC Support and Advocacy - (213) 821-4710
uscsa.usc.edu
Assists students and families in resolving complex personal, financial, and academic issues adversely affecting their success as a student.

Diversity at USC - (213) 740-2101
diversity.usc.edu
Information on events, programs and training, the Provost’s Diversity and Inclusion Council, Diversity Liaisons for each academic school, chronology, participation, and various resources for students.

USC Emergency - UPC: (213) 740-4321, HSC: (323) 442-1000 – 24/7 on call
dps.usc.edu, emergency.usc.edu
Emergency assistance and avenue to report a crime. Latest updates regarding safety, including ways in which instruction will be continued if an officially declared emergency makes travel to campus infeasible.

USC Department of Public Safety - UPC: (213) 740-6000, HSC: (323) 442-120 – 24/7 on call
dps.usc.edu
Non-emergency assistance or information.